What’s Hot & What’s Not in Oncology Licensing

September 18, 2014


  • Linda Pullan, Ph.D, Pullan Consulting
  • Jeffrey M. Bockman, PhD, Executive Vice President, Head of Oncology Practice


  • Paul Juniewicz, Vice President, Oncology Business Opportunities, MD Anderson
  • Ferran Prat, Ph.D, VP of Strategic Industry Ventures, MD Anderson

This panel discussion will be a lively Q&A on what is exciting in cancer drug development and what is not popular in licensing, and why.

Biotech and pharmaceutical consultant Linda Pullan will be joined by three panelists who are business development experts from a global pharmaceutical company, a leading academic cancer center, and a top business development consulting firm. The panelists will discuss theories of cancer, favorite targets and modalities, the impact of reimbursement, deal types, and more.

If you are developing a cancer drug or working toward in- or out-licensing of a cancer drug, you will want to hear these perspectives.